NCT06184269View on ClinicalTrials.gov

"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1017-1 and Co-administration of BR1017-1A and BR1017-1B"

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 23, 2023

Primary Completion Date

February 18, 2024

Study Completion Date

February 18, 2024

Conditions
Essential HypertensionPrimary Hypercholesterolemia
Interventions
DRUG

BR1017-1

One tablet administered alone

DRUG

BR1017-1A

One tablet administered alone

DRUG

BR1017-1B

One tablet administered alone

Trial Locations (1)

08779

Clinical Research Center, H PLUS Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT06184269 - "A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1017-1 and Co-administration of BR1017-1A and BR1017-1B" | Biotech Hunter | Biotech Hunter